Viimeisimmät artikkelit
- Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajille
- Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland
- Desentum raised 12 million euros for advancing allergy vaccine development
- Desentum announces full recruitment of a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy
- First subjects dosed in a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy
Viimeisimmät kommentit
No comments to show.